LYEL

Lyell Immunopharma Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Lyell Immunopharma sales and earnings growth
LYEL Growth
Low
  • Revenue Y/Y↓ -43.33%
  • EPS Y/Y↓ -45.05%
  • FCF Y/Y↓ -5.79%
Lyell Immunopharma gross and profit margin trends
LYEL Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -957823.50%
  • ROIC↓ -101.30%
Lyell Immunopharma net debt vs free cash flow
LYEL Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Lyell Immunopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗